aTyr Pharma Inc (NASDAQ:LIFE) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 121,000 shares, a growth of 7.3% from the August 30th total of 112,800 shares. Based on an average daily volume of 92,900 shares, the days-to-cover ratio is presently 1.3 days. Currently, 3.8% of the shares of the company are short sold.
Several equities research analysts have commented on the stock. Citigroup set a $4.00 price target on shares of aTyr Pharma and gave the company a “hold” rating in a research note on Friday, August 30th. ValuEngine upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd.
Shares of NASDAQ LIFE traded up $0.22 during mid-day trading on Tuesday, reaching $3.25. 1,239 shares of the company traded hands, compared to its average volume of 20,824. aTyr Pharma has a fifty-two week low of $2.76 and a fifty-two week high of $11.48. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a fifty day simple moving average of $3.39 and a 200-day simple moving average of $2.14.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wedbush Securities Inc. increased its stake in shares of aTyr Pharma by 158.7% during the second quarter. Wedbush Securities Inc. now owns 67,270 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 41,271 shares during the period. Vanguard Group Inc. increased its stake in shares of aTyr Pharma by 1.9% during the second quarter. Vanguard Group Inc. now owns 1,779,024 shares of the biotechnology company’s stock valued at $652,000 after acquiring an additional 33,702 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of aTyr Pharma by 19.8% during the second quarter. Renaissance Technologies LLC now owns 1,845,873 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 305,314 shares during the period.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Featured Article: Treasury Bonds
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.